SUBSCRIBE
SUBSCRIBE

Inflammatory bowel disease

Drug Development
Inflammatory Bowel Disease Insight Report: Current Therapies, Drug Pipeline and Outlook
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
November 18, 2019
 · 
33 min read
 · 
Tracy Lawton
Drug Development
Provention Bio’s Crohn’s Disease Drug Flunks Mid-Stage Trial
The drug showed what the company is calling a “substantial improvement in this symptom-driven score” at the 12-week point, but it did not differentiate from placebo.
October 23, 2019
 · 
3 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Press Releases
Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease
January 8, 2025
 · 
7 min read
Press Releases
Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease
December 18, 2024
 · 
10 min read
Press Releases
Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation
December 12, 2024
 · 
6 min read
Press Releases
Orphagen Pharmaceuticals Receives NIH Funding Award to Advance a Novel Drug for Inflammatory Bowel Disease
December 9, 2024
 · 
4 min read
Press Releases
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
December 3, 2024
 · 
8 min read
Press Releases
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease
November 29, 2024
 · 
4 min read
Press Releases
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
November 19, 2024
 · 
6 min read
Press Releases
Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock
November 19, 2024
 · 
5 min read
Press Releases
Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
November 15, 2024
 · 
3 min read
Press Releases
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024
November 12, 2024
 · 
1 min read
Press Releases
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
November 11, 2024
 · 
2 min read
Press Releases
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
November 4, 2024
 · 
4 min read
Press Releases
Spyre Therapeutics to Participate in Upcoming November 2024 Investor Conferences
October 31, 2024
 · 
1 min read
Press Releases
TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn’s disease
October 29, 2024
 · 
15 min read
Press Releases
Odyssey Therapeutics to Present New Data on its Clinical-Stage RIPK2 Scaffolding Inhibitor, OD-07656, at the American College of Gastroenterology (ACG) Annual Scientific Meeting 2024
October 28, 2024
 · 
3 min read
Press Releases
Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells
October 17, 2024
 · 
4 min read
Press Releases
Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease
October 15, 2024
 · 
6 min read
Press Releases
Biora Therapeutics Announces Funding Agreement with Existing Investors
October 15, 2024
 · 
4 min read
Press Releases
Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre’s Portfolio of Potentially Best-in-Class Antibodies and Combinations
October 15, 2024
 · 
7 min read
Press Releases
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
September 27, 2024
 · 
6 min read
Load More